Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer.
Elias AD, Staley AW, Fornier M, Vidal GA, Alami V, Sams S, Spoelstra NS, Goodspeed A, Kabos P, Diamond JR, Shagisultanova E, Gallagher RI, Wulfkuhle JD, Petricoin EF, Zolman KL, McSpadden T, Jordan KR, Slansky JE, Borges VF, Gao D, Richer JK. Elias AD, et al. Among authors: spoelstra ns. NPJ Breast Cancer. 2024 Oct 6;10(1):88. doi: 10.1038/s41523-024-00697-5. NPJ Breast Cancer. 2024. PMID: 39368973 Free PMC article.
Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity.
Kuo LW, Crump LS, O'Neill K, Williams MM, Christenson JL, Spoelstra NS, Roy MK, Argabright A, Reisz JA, D'Alessandro A, Boorgula MP, Goodspeed A, Bickerdike M, Bitler BG, Richer JK. Kuo LW, et al. Among authors: spoelstra ns. Cancer Res Commun. 2024 Oct 1;4(10):2699-2713. doi: 10.1158/2767-9764.CRC-24-0272. Cancer Res Commun. 2024. PMID: 39311710 Free PMC article.
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.
Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Elias AD, et al. Among authors: spoelstra ns. NPJ Breast Cancer. 2023 May 20;9(1):41. doi: 10.1038/s41523-023-00544-z. NPJ Breast Cancer. 2023. PMID: 37210417 Free PMC article.
NPC1 Confers Metabolic Flexibility in Triple Negative Breast Cancer.
O'Neill KI, Kuo LW, Williams MM, Lind H, Crump LS, Hammond NG, Spoelstra NS, Caino MC, Richer JK. O'Neill KI, et al. Among authors: spoelstra ns. Cancers (Basel). 2022 Jul 21;14(14):3543. doi: 10.3390/cancers14143543. Cancers (Basel). 2022. PMID: 35884604 Free PMC article.
Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
Christenson JL, O'Neill KI, Williams MM, Spoelstra NS, Jones KL, Trahan GD, Reese J, Van Patten ET, Elias A, Eisner JR, Richer JK. Christenson JL, et al. Among authors: spoelstra ns. Mol Cancer Ther. 2021 Jun;20(6):1062-1071. doi: 10.1158/1535-7163.MCT-20-0807. Epub 2021 Mar 15. Mol Cancer Ther. 2021. PMID: 33722849 Free PMC article.
43 results